GLP-1 Muscle Loss: How to Preserve Lean Mass, Strength & Metabolic Health
GLP-1-based medications have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as these medicines become more widely used, another question has become increasingly important:
How much of the weight lost on a GLP-1 drug comes from muscle or other lean tissue—and can that loss be minimized?
The evidence shows a nuanced answer.
People taking semaglutide, tirzepatide and related incretin-based medicines generally lose much more fat than lean tissue. At the same time, absolute lean mass usually falls during substantial weight loss. Importantly, lean mass is not the same thing as skeletal muscle: DXA-based “lean mass” also includes water, organs and other non-fat tissues. Therefore, a finding that lean mass decreased does not automatically mean that the same amount of skeletal muscle was lost.
Recent 2026 meta-analyses suggest that roughly one-quarter to one-third of total weight lost with incretin therapy may be classified as lean mass, with substantial variation between studies and drugs. The proportion is broadly similar to conventional lifestyle weight loss, while programs that include resistance training appear to produce a more favorable distribution of weight loss.
The practical message is therefore not “avoid GLP-1 drugs because they destroy muscle.” Rather:
The goal should be high-quality weight loss: lose excess fat while protecting muscle mass, strength, physical function and nutritional adequacy.
Quick answer: Do GLP-1 drugs cause muscle loss?
They can be associated with a reduction in lean mass during weight loss, but the evidence does not show that GLP-1 therapy simply causes widespread or disproportionate muscle wasting.
Large reductions in body fat generally accompany the reduction in lean tissue. In the STEP 1 body-composition substudy, semaglutide reduced total fat mass by 19.3% and total lean body mass by 9.7%; because fat fell more substantially, the proportion of the body made up of lean mass actually increased by about 3 percentage points.
In the SURMOUNT-1 DXA substudy, tirzepatide reduced body weight by 21.3%, fat mass by 33.9% and lean mass by 10.9% at 72 weeks. Approximately 75% of the weight lost was fat and 25% was lean mass.
A 2026 meta-analysis of 20 randomized trials involving 15,782 participants found that lean mass represented approximately:
35.2% of weight lost with semaglutide
25.4% with tirzepatide
26.8% with liraglutide
26.2% with lifestyle interventions
17.5% with lifestyle interventions that incorporated resistance training
These figures should not be interpreted as percentages of skeletal muscle loss. They refer to measured lean mass, and the methods and populations differed between studies.
Why does lean mass fall during weight loss?
Any substantial weight-loss intervention can reduce lean tissue.
When calorie intake falls, the body draws on stored energy. Fat stores supply much of that energy, but reductions in body weight also alter water, glycogen, organ mass and lean soft tissue. Some loss of lean tissue therefore occurs even when weight loss is desirable and metabolically beneficial.
.png)
GLP-1-based medicines can amplify this process because they reduce appetite and food intake. Nausea, early fullness and gastrointestinal symptoms can also make it harder for some people to consume enough protein and total nutrition. Recent expert reviews emphasize that reduced food intake—not proven direct muscle toxicity—is the central issue when considering lean-mass preservation during incretin-based weight loss.
This distinction matters.
Losing lean mass does not automatically mean losing large amounts of skeletal muscle
“Lean mass,” “fat-free mass,” “lean soft tissue” and “skeletal muscle mass” are related but different measurements.
For example, DXA can estimate lean soft tissue, but it does not directly tell us how much of the change came from skeletal muscle versus water and other tissues. MRI and CT can provide more direct information about muscle volume, but these methods are less commonly incorporated into large obesity trials.
That is why headlines such as “40% of GLP-1 weight loss is muscle” can be misleading.
A better statement is:
A meaningful portion of weight lost during GLP-1-based treatment can be classified as lean mass, but current evidence does not support equating all of that lean-mass reduction with skeletal-muscle loss.
What does the research show?
1. Semaglutide: STEP 1 body-composition study
The STEP 1 trial established semaglutide 2.4 mg as a highly effective obesity treatment. A DXA substudy involving 140 participants examined body composition over 68 weeks.
Among participants receiving semaglutide:
Body weight fell approximately 15%
Total fat mass fell 19.3%
Visceral fat mass fell 27.4%
Lean body mass fell 9.7%
The proportion of body weight represented by lean mass increased by about 3 percentage points
The interpretation is important: fat loss was substantially greater than lean-mass loss.
The study therefore provides evidence for substantial fat loss accompanied by some lean-mass reduction, rather than evidence that semaglutide selectively destroys muscle.
2. Tirzepatide: SURMOUNT-1 body-composition study
Tirzepatide provides another useful data point because its weight-loss effects are large.
In the SURMOUNT-1 DXA substudy, 160 participants were evaluated at baseline and week 72. Tirzepatide produced:
21.3% reduction in body weight
33.9% reduction in fat mass
10.9% reduction in lean mass
Approximately three-quarters of the weight lost was fat mass and one-quarter was lean mass. The investigators found that this proportion was relatively consistent across several demographic and weight-loss subgroups.
Again, however, the DXA measurement should not be interpreted as equivalent to pure skeletal-muscle measurement.
3. What do the 2026 meta-analyses tell us?
The emerging evidence is remarkably consistent on one point:
Some lean mass is normally lost during major weight reduction, regardless of whether the weight loss comes from medication or lifestyle intervention.
A 2026 systematic review and meta-analysis of randomized trials comparing incretin therapy with lifestyle interventions found that lean mass constituted approximately 25–39% of total weight loss with incretin agonists. The proportion was broadly comparable with lifestyle treatment. Adding resistance training produced a more favorable composition of weight loss, with lean mass accounting for about 17.5% of total weight lost in the analyzed studies.
Another 2026 meta-analysis focusing specifically on GLP-1 receptor agonists found that absolute lean mass decreased overall, while lean mass as a proportion of total body weight increased. The authors concluded that lean-mass loss should be addressed with nutritional and exercise interventions rather than treated as a reason to avoid effective obesity pharmacotherapy.
Taken together, these studies support a more sophisticated way of thinking about “muscle loss.”
The key question is not simply:
How many kilograms of lean mass were lost?
It is also:
Did the person preserve strength, physical function, adequate nutrition and a healthy proportion of lean tissue while losing substantially more excess fat?
4. A newer semaglutide study adds an important piece: muscle function
The 2026 SEMALEAN study followed adults with obesity receiving semaglutide 2.4 mg and assessed weight, DXA body composition and handgrip strength over 12 months.
Among the 106 participants who completed the study:
Weight decreased approximately 10% at 7 months and 13% at 12 months
Fat mass decreased approximately 14% at 7 months and 18% at 12 months
Lean mass initially declined by about 3 kg, then stabilized
Handgrip strength increased by approximately 4.5 kg at 12 months
The proportion classified as having sarcopenic obesity decreased from 49% to 33%
These findings are encouraging because they demonstrate that a decline in lean mass does not necessarily translate into declining muscle strength. However, SEMALEAN was a prospective observational study without the same randomized control design as a large phase 3 trial, so its results should not be interpreted as definitive proof that semaglutide improves muscle function.
This distinction is crucial.
Body composition and physical function are not the same endpoint.
Is GLP-1 muscle loss dangerous?
Not necessarily.
For someone with obesity, losing substantial amounts of excess adipose tissue can produce major health benefits even when some lean tissue is lost. Weight reduction can improve blood pressure, glucose regulation, sleep apnea, fatty liver disease, cardiovascular risk and physical mobility.
The potential concern becomes greater when lean-mass loss is accompanied by:
Declining strength
Difficulty climbing stairs or rising from a chair
Reduced walking capacity
Falls or instability
Frailty
Inadequate protein or micronutrient intake
Significant fatigue or weakness
Pre-existing sarcopenia
Advanced age
Very low calorie intake
Rapid or poorly tolerated weight loss
The goal therefore should not be zero lean-mass loss, which may be unrealistic during substantial weight reduction.
The goal is preserving as much functional muscle as possible while achieving clinically meaningful fat loss.
Who should be especially careful about muscle preservation?
Some people deserve closer attention to lean mass and strength during GLP-1-based weight loss.
Older adults
Aging is associated with declining muscle mass, strength and physical reserve. This means a modest additional loss may have greater functional consequences in an older adult than in a younger person.
Recent expert consensus on incretin-based therapy emphasizes nutritional adequacy and progressive resistance exercise, particularly when reduced appetite and rapid weight loss create nutritional or functional risks.
People with pre-existing sarcopenia
Someone who already has low muscle strength or low muscle mass may have less physiological reserve.
For these individuals, weight loss should be monitored for quality—not simply speed.
People losing weight very rapidly
Very rapid weight reduction increases the importance of adequate protein, resistance exercise, hydration and nutritional monitoring.
People who struggle to eat
Some patients experience substantial appetite suppression, nausea or early satiety. If food intake becomes very low, protein and micronutrient adequacy can become difficult to maintain.
People with a history of bariatric surgery
The SEMALEAN study found particularly pronounced body-composition changes in participants with previous bariatric surgery, although this subgroup requires further study.
The most important strategy: resistance training
Among all the approaches used to preserve muscle during weight loss, resistance exercise has some of the strongest supporting evidence.
A 2025 systematic review and meta-analysis of 25 randomized trials found that adding resistance exercise to dietary weight loss:
Protected against loss of fat-free mass
Increased fat-mass loss
Improved muscular strength
The evidence for preservation of fat-free mass was rated moderate certainty, while the evidence for increased fat-mass loss was high certainty.
This evidence is not exclusively from people taking GLP-1 drugs. That is an important limitation.
However, because GLP-1 therapy induces substantial weight loss partly through reduced energy intake, the physiological rationale for resistance exercise during pharmacological weight loss is strong.
A practical starting point
For an otherwise healthy adult, a reasonable muscle-preservation framework can include:
2–3 resistance-training sessions per week
Focus on major movement patterns:
Squat or sit-to-stand
Hip hinge
Push
Pull
Carry
Calf/ankle work
Core/trunk stability
Begin at a manageable level and gradually increase resistance, repetitions or training volume.
The World Health Organization recommends muscle-strengthening activities involving the major muscle groups on at least two days per week for adults.
A person who is frail, severely deconditioned, injured or has significant cardiovascular, orthopedic or neurological disease may need individualized guidance from a clinician or qualified exercise professional.
What about walking and cardio?
Walking and aerobic exercise remain valuable.
They can improve cardiovascular fitness, insulin sensitivity, mobility and overall health. They may also help maintain daily activity during weight loss.
But cardio alone is not a substitute for resistance training when the specific objective is to preserve muscle.
A balanced program can therefore combine:
Resistance exercise → muscle and strength
Aerobic activity → cardiovascular fitness and endurance
Daily movement → mobility and energy expenditure
The ideal program is sustainable rather than extreme.
Protein: how much do you need?
Adequate protein becomes particularly important when appetite and total calorie intake decrease.
A 2026 clinical nutrition review focusing specifically on GLP-1-based therapy proposed a pragmatic protein intake of approximately 1.2–1.6 g/kg/day for appropriate adults without chronic kidney disease, with individualized meal-level targets.
However, this is a practical expert recommendation—not a universally proven GLP-1-specific dose.
The appropriate amount varies with:
Age
Body size
Kidney function
Activity level
Resistance-training status
Dietary pattern
Total energy intake
Existing muscle mass
Medical conditions
For older adults, earlier evidence-based consensus recommendations have commonly suggested at least 1.0–1.2 g/kg/day, with higher intake often considered during illness or periods of increased nutritional stress.
For people with chronic kidney disease, protein targets should be individualized with a healthcare professional rather than automatically following a high-protein diet.
One practical problem with GLP-1 therapy
It is possible to hit a protein target on paper but still have poor nutritional quality.
Someone eating very little may choose foods that are convenient but low in protein. Because appetite is suppressed, every meal becomes more important.
Good protein-rich choices include:
Greek yogurt or other high-protein dairy
Eggs
Fish
Chicken and other lean meats
Soy foods
Tofu and tempeh
Beans and lentils
Cottage cheese
High-protein nutritional supplements when medically appropriate
A registered dietitian can help tailor protein intake to body size, kidney function and dietary preferences.
Should protein be spread throughout the day?
Potentially.
The 2026 medical-nutrition review proposed meal-wise protein targets around 0.3–0.4 g/kg per meal together with attention to overall daily intake.
The broader physiological rationale is that muscle protein synthesis responds to adequate protein doses rather than simply to a large single protein intake at the end of the day.
For a person with low appetite, spreading protein across several smaller meals may therefore be easier than trying to consume a large amount at dinner.
What about leucine?
Leucine is an essential amino acid involved in stimulating muscle protein synthesis.
Some nutrition experts have suggested that meals containing roughly 2.5–3 g of leucine may help provide a robust anabolic signal in appropriate individuals.
However, this does not mean people taking GLP-1 drugs need to buy isolated leucine supplements.
Adequate high-quality protein generally provides leucine naturally.
The priority should be:
Total protein adequacy → adequate calories and micronutrients → resistance training → individualized supplementation when appropriate.
What about creatine?
Creatine is one of the better-studied sports-nutrition supplements for supporting strength and lean tissue when combined with resistance training.
Importantly, however, direct evidence that creatine specifically prevents GLP-1-associated muscle loss is currently limited.
Evidence from older adults is more encouraging. Recent systematic reviews have reported improvements in some strength outcomes when creatine is combined with resistance training, although newer 2026 analyses found that additional effects on muscle mass and physical function remain less certain.
Therefore:
Creatine may be reasonable for selected adults, particularly those performing resistance training, but it should not be presented as a proven GLP-1 muscle-loss treatment.
People with kidney disease or other medical conditions should discuss supplementation with their healthcare professional.
Do you need a DXA scan?
Not everyone needs one.
A scale measures body weight. It does not tell you whether weight loss came from fat, lean tissue or changes in hydration.
DXA* can provide a more useful estimate of:
Fat mass
Lean soft tissue
Bone mineral content
Regional body composition
But DXA still does not directly measure every kilogram of skeletal muscle.
More sophisticated MRI or CT techniques can assess specific muscle compartments, but they are less practical for routine monitoring.
Who might benefit most from body-composition assessment?
It may be particularly useful for people with:
Older age
Suspected sarcopenia
Previous bariatric surgery
Very large or rapid weight loss
Unexplained weakness
Significant nutritional concerns
A clinical reason to monitor lean tissue
Monitoring should be individualized rather than turning DXA into a routine requirement for every GLP-1 user.
*Note: DEXA vs. DXA: Is There a Difference? DEXA and DXA refer to the same bone density test. DXA is the official medical abbreviation for Dual-energy X-ray Absorptiometry. The "E" is added informally to spell out "dual-energy" (D-E-XA). Both terms are used interchangeably by doctors, clinics, and health guides.Strength may be more important than the number on a body-composition report
This is one of the most important lessons emerging from the research.
Imagine two people who each lose 15 kg.
Person A:
Loses mostly fat, maintains strength, walks normally and can still climb stairs.
Person B:
Loses the same amount of weight but experiences substantial strength loss, reduced mobility and functional decline.
Their scale readings are identical.
Their outcomes are not.
That is why future GLP-1 studies increasingly need to evaluate not only body weight but also:
muscle mass + muscle strength + physical function + nutritional status
rather than treating weight loss alone as the complete outcome.
How to know whether you may be losing too much muscle
There is no single home test that can reliably diagnose clinically important muscle loss.
However, several changes deserve attention.
Possible warning signs
Strength is declining rather than improving
Everyday activities become harder
You have difficulty rising from a chair
Stairs become substantially harder
You are falling more often
Walking speed decreases
You feel persistently weak
Your appetite is so suppressed that adequate food intake becomes difficult
You are losing weight rapidly while eating very little
Clothing becomes looser but functional capacity also declines
These signs do not prove that muscle loss is occurring, but they warrant discussion with your healthcare team.
A practical GLP-1 muscle-preservation plan
Step 1: Make protein a priority
Build each meal around a meaningful protein source.
Rather than trying to dramatically increase protein overnight, establish a consistent intake that fits your medical needs.
Step 2: Strength train at least twice weekly
Prioritize major muscle groups and progressively challenge them.
Consistency matters more than complicated workouts.
Step 3: Keep moving
Walking, cycling, swimming and other aerobic activities support cardiovascular health and physical function.
Step 4: Avoid unnecessarily aggressive calorie restriction
GLP-1 therapy already suppresses appetite.
Eating as little as possible is not the objective.
The objective is clinically meaningful fat loss while maintaining adequate nutrition.
Step 5: Monitor strength, not just weight
A shrinking waist combined with maintained or improving strength is generally more informative than scale weight alone.
Step 6: Address gastrointestinal side effects
Persistent nausea, vomiting or early satiety can make adequate protein and micronutrient intake difficult.
Discuss significant or persistent symptoms with your prescriber.
Step 7: Reassess the plan when weight loss is very rapid
Rapid weight reduction is not automatically harmful, but very low food intake, weakness or declining function should prompt reassessment.
Can you actually build muscle while taking a GLP-1?
Possibly.
There is not yet enough high-quality evidence to promise that GLP-1 therapy itself increases skeletal muscle mass.
But a person who is losing fat while resistance training and consuming adequate protein may be able to maintain or potentially increase muscle and strength, particularly when beginning from a relatively untrained state.
The 2026 SEMALEAN study found improved handgrip strength despite an initial reduction in measured lean mass, illustrating why muscle function cannot be inferred from body-composition data alone.
This is one of the most interesting areas for future clinical research.
Does tirzepatide cause more muscle loss than semaglutide?
The available data do not support a simple conclusion that one drug is inherently more harmful to muscle.
Different trials have different:
Participants
Baseline body weights
Treatment durations
Weight-loss magnitudes
Body-composition techniques
Statistical estimands
For example, the SURMOUNT-1 DXA substudy found a 10.9% reduction in lean mass with tirzepatide, while the STEP 1 DXA analysis found a 9.7% reduction in lean body mass with semaglutide. But those figures come from different studies and cannot be interpreted as a head-to-head comparison.
The most informative head-to-head question is not simply:
Which drug causes the least muscle loss?
It is:
How do different treatments affect fat mass, lean mass, strength and physical function when studied under comparable conditions?
That question remains incompletely answered.
Does greater weight loss mean greater muscle loss?
Generally, greater weight loss means more absolute tissue is lost, including some lean tissue.
But greater weight loss does not necessarily mean a greater proportion of weight loss comes from lean tissue.
In STEP 1, greater weight reduction was associated with a more favorable lean-mass-to-fat-mass ratio.
The 2026 meta-analysis of incretin therapies likewise found substantial differences among individuals and treatments, reinforcing that total weight lost and quality of weight lost are related but distinct concepts.
What does the evidence say about GLP-1 drugs and sarcopenia?
This is an area where caution is appropriate.
Obesity and sarcopenia can coexist.
This is sometimes called sarcopenic obesity—excess adiposity accompanied by low muscle mass, low muscle strength or impaired physical function.
Weight loss can be beneficial for a person with sarcopenic obesity, but the treatment strategy needs to protect physical function.
The SEMALEAN study reported a reduction in the prevalence of sarcopenic obesity during 12 months of semaglutide treatment, from 49% to 33%, alongside significant fat loss and improved handgrip strength.
That finding illustrates why simply assuming “weight loss = sarcopenia” is incorrect.
At the same time, studies in people at high risk of sarcopenia remain limited, so clinicians should not assume that all populations respond identically.
The importance of exercise during GLP-1 treatment
A key finding from the broader weight-loss literature is that exercise can change the composition of weight lost.
In the 2026 meta-analysis comparing incretin therapy and lifestyle approaches, lifestyle interventions combined with resistance training had the lowest proportion of total weight loss attributed to lean mass among the analyzed treatment strategies.
Similarly, a 2025 meta-analysis found that resistance exercise during dietary weight loss protected fat-free mass and improved muscle strength.
This leads to a practical principle:
Do not think of the GLP-1 medication and exercise as competing approaches. For many patients, the combination may produce higher-quality weight loss than either strategy considered in isolation.
What about bone health?
Bone is another reason not to judge weight-loss treatment solely by the scale.
Weight loss can influence bone density, particularly in people who are older or who lose weight rapidly. Current musculoskeletal reviews of incretin therapy have not established a clear harmful effect of GLP-1 drugs on fracture outcomes, but longer-term data remain limited. A 2026 systematic review found no significant overall effect on bone mineral density or fracture outcomes in its most adjusted analyses, while lean-mass reductions were more consistently observed.
Weight-bearing activity, resistance exercise, adequate nutrition and attention to vitamin D and calcium status therefore remain relevant components of healthy weight management.
What remains unknown?
Despite the rapidly growing literature, several important questions remain unanswered.
1. How much of measured lean-mass loss is actual skeletal-muscle loss?
Current trials frequently use DXA. More MRI-based research is needed.
2. Does lean-mass loss translate into worse physical function?
Not necessarily.
The SEMALEAN findings demonstrate why strength and functional measurements are important.
3. Can resistance training completely prevent muscle loss?
Probably not in every individual.
But the evidence strongly supports resistance training as a strategy to attenuate lean-tissue loss during calorie restriction. The magnitude of protection specifically during GLP-1 therapy remains an active research question.
4. What is the optimal protein target for people taking GLP-1 drugs?
There is growing expert guidance, but no universally established GLP-1-specific protein dose for every patient. Individualization remains important.
5. What happens after long-term treatment?
As GLP-1 therapy is increasingly used for years rather than months, long-term muscle, bone and functional outcomes will become increasingly important research endpoints.
6. Which patients are most vulnerable?
Older adults, people with pre-existing low muscle mass, those with very low protein intake and people experiencing substantial nutritional restriction deserve particular attention.
The bottom line
GLP-1 medications can produce substantial reductions in body weight, and some of that weight loss is lean mass.
But the evidence does not support the simplistic statement that GLP-1 drugs “cause massive muscle loss.”
The more accurate interpretation is:
1. Fat loss generally exceeds lean-mass loss.
2. Some lean mass is commonly lost during substantial weight reduction.
3. Lean mass is not equivalent to skeletal muscle.
4. Muscle strength and physical function may be maintained or improved even when measured lean mass decreases.
5. Resistance exercise is one of the strongest evidence-based tools for protecting lean tissue and strength during weight loss.
6. Adequate protein and overall nutritional intake are important, especially when appetite is strongly suppressed.
7. Older adults and people with pre-existing sarcopenia require particular attention to muscle preservation.
8. The best measure of successful GLP-1 treatment is not simply “How many kilograms did I lose?” but “How much excess fat did I lose while preserving strength, function and nutritional health?”
The emerging concept is therefore quality weight loss rather than weight loss alone.
For people using GLP-1-based obesity treatment, the combination of appropriate medication, adequate nutrition, resistance training, physical activity and individualized monitoring may offer a better framework for protecting the body’s metabolic and functional reserve.
Frequently Asked Questions
Does Ozempic cause muscle loss?
Semaglutide can be associated with a reduction in measured lean mass during weight loss. In a DXA substudy of STEP 1, lean body mass fell 9.7%, while fat mass fell 19.3%. Importantly, the proportion of body weight represented by lean mass increased.
Ozempic is semaglutide marketed for type 2 diabetes, while higher-dose semaglutide for chronic weight management is marketed under other product indications. The specific drug, dose and treatment population matter when interpreting studies.
Does Wegovy cause muscle loss?
Wegovy contains semaglutide, and semaglutide-associated weight loss can include some loss of lean mass. Current evidence does not establish that the drug causes disproportionate skeletal-muscle wasting.
Does Mounjaro or Zepbound cause muscle loss?
Tirzepatide treatment has been associated with reductions in lean mass during weight loss. In the SURMOUNT-1 DXA substudy, approximately 75% of weight lost was fat and 25% was lean mass.
How do I prevent muscle loss on a GLP-1?
The main evidence-supported strategies are adequate protein intake, progressive resistance training and avoiding unnecessarily severe nutritional restriction. Body-composition and strength monitoring may be useful in people at elevated risk.
How much protein should I eat on a GLP-1?
There is no single dose appropriate for everyone. A 2026 clinical nutrition review proposed approximately 1.2–1.6 g/kg/day for appropriate adults without chronic kidney disease, but protein needs should be individualized according to body size, age, activity and medical conditions.
Is resistance training better than cardio for preventing muscle loss?
For preserving lean tissue and strength during weight loss, resistance training has particularly strong evidence. Aerobic exercise remains important for cardiovascular fitness and overall health, so many people benefit from combining both.
Should I take creatine while using a GLP-1 drug?
Creatine has evidence supporting strength benefits when combined with resistance training, particularly in older adults, but there is not yet strong direct evidence that it specifically prevents GLP-1-associated muscle loss.
Can I gain muscle while losing weight on a GLP-1?
It is possible, particularly for people beginning resistance training, but it should not be assumed. The most realistic goal during substantial weight loss is often maintaining or improving strength while reducing excess fat.
Should everyone taking a GLP-1 get a DXA scan?
No. DXA can be useful when there is a specific clinical reason to evaluate body composition, but it is not necessary for every person using a GLP-1 drug.
What are signs that I may be losing too much muscle?
Declining strength, difficulty climbing stairs or rising from a chair, falls, reduced walking ability, persistent weakness and inadequate food intake are reasons to discuss the treatment plan with a healthcare professional.
Evidence snapshot
| Evidence | Population / design | Main finding | What it means |
|---|---|---|---|
| STEP 1 DXA substudy | Semaglutide 2.4 mg, 68 weeks | Fat mass −19.3%; lean mass −9.7%; lean-mass proportion increased | Fat loss exceeded lean-mass loss |
| SURMOUNT-1 DXA substudy | Tirzepatide, 72 weeks | Weight −21.3%; fat −33.9%; lean −10.9% | ~75% of weight lost was fat |
| 2026 incretin meta-analysis | 20 RCTs; 15,782 participants | Lean mass 25–39% of total weight loss | Lean-mass loss occurs with major weight reduction, but is broadly comparable with lifestyle treatment |
| 2026 GLP-1 meta-analysis | 7 RCTs; 821 participants | Absolute lean mass decreased, while relative lean-mass proportion improved | Body-composition quality is more nuanced than kilograms of lean mass alone |
| SEMALEAN 2026 | 106 semaglutide-treated adults; 12 months | Lean mass initially fell then stabilized; grip strength +4.5 kg | Function may improve despite some measured lean-mass loss |
| Resistance exercise meta-analysis | 25 RCTs during dietary weight loss | Protected fat-free mass and improved strength | Strong rationale for resistance training during weight loss |
Evidence quality: what we know vs. what we don't
Higher confidence
GLP-1-based therapies can produce substantial weight loss.
Fat mass generally falls more than lean mass.
Some measurable lean mass is lost during substantial weight reduction.
Resistance exercise helps preserve fat-free mass and strength during weight loss.
Adequate nutritional and protein intake is important during appetite-suppressing therapy.
Moderate or emerging evidence
The exact amount of skeletal-muscle loss caused by individual GLP-1 therapies.
Whether certain incretin drugs are consistently better or worse for muscle.
Whether lean-mass changes translate into meaningful long-term functional impairment.
The optimal protein prescription specifically for GLP-1-treated patients.
The role of supplements such as creatine specifically in GLP-1 users.
Still being investigated
Long-term muscle quality and physical performance over several years.
MRI-defined changes in individual muscle groups.
Strategies combining GLP-1 therapy with dedicated muscle-preserving interventions.
Whether future obesity medications can selectively reduce fat while preserving or increasing skeletal muscle.
Practical takeaway
GLP-1 therapy should not be viewed as a choice between losing weight and preserving muscle.
The more useful goal is to make weight loss metabolically and functionally high quality:
Medication → reduce excess adiposity
Protein → provide building blocks
Resistance training → provide the muscle-preservation signal
Aerobic activity → support cardiovascular fitness
Adequate nutrition → prevent deficiencies
Monitoring → identify excessive loss of strength or lean tissue
For most people, the ideal outcome is not the smallest possible number on the scale.
It is less visceral and total body fat, preserved muscle and strength, adequate nutrition, better mobility and improved long-term metabolic health.
Medical note
This article is for educational purposes and is not a substitute for individualized medical or nutrition advice. People taking GLP-1-based medicines who develop significant weakness, persistent vomiting, difficulty eating, dehydration, falls or major functional decline should contact their healthcare professional. Protein requirements and exercise plans should be individualized for people with kidney disease, frailty, major chronic illness or other medical conditions.
Related OneDayMD evidence hub: GLP-1 Clinical Trials & Studies
.png)
Comments
Post a Comment